Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
How It Works 
News - Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
AbbVie Inc(ABBV)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for ABBV
10/28/2026: ABBV (4-star) is a STRONG-BUY. BUY for 109 days. Simulated Profits (35.98%). Updated daily EoD!
AbbVie is a prominent, research-based biopharmaceutical company that has historically relied on the success of its flagship immunology drug, Humira. The company is currently executing a strategic pivot, leveraging newer blockbusters like Skyrizi and Rinvoq, alongside its diversified aesthetics franchise obtained from the acquisition of Allergan. While AbbVie benefits from high profit margins and a long track record of consistent dividend payments, it faces substantial risks, including patent cliffs and intense competition from biosimilar manufacturers. The company is best suited for income-focused and value-oriented investors who can tolerate sector-specific regulatory and clinical risks while monitoring the successful integration of its new growth drivers.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | Growth is moderate as the company focuses on replacing legacy revenue rather than aggressive top-line expansion. |
| Momentum investor | Mixed fit | Momentum is conditional on positive clinical data readouts and the successful uptake of new products like Skyrizi. |
| Value investor | Strong fit | AbbVie often trades at a valuation that appeals to value investors seeking steady cash flows and a solid yield. |
| Dividend investor | Strong fit | The company's history of consistent dividend increases makes it a preferred choice for income-focused portfolios. |
| Low-risk investor | Mixed fit | While established, the company faces patent risk and regulatory uncertainty which can introduce volatility. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | Medium | Biotech stocks are sensitive to clinical trial outcomes and regulatory news. |
| Valuation risk | Medium | The stock can become overvalued if investors overestimate the growth potential of new pipelines. |
| Competition risk (biosimilars) | High | The entry of lower-cost biosimilars directly impacts the pricing power of core immunology assets. |
| Business quality | Strong | AbbVie maintains high profit margins and a defensible, albeit pressured, product moat. |
| Dividend income | Strong | The dividend is supported by robust cash flows, making it highly reliable. |
| Execution risk | Medium / high | Successful transition from Humira to newer blockbusters is critical for long-term health. |
Price Behavior
Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.
Smooth
The stock has moved along a generally orderly path with only modest fluctuations.
Analysis of Past Performance
Type Stock | Historic Profit 48.56% | Avg. Invested days 50 | Today’s Advisory Strong Buy |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/28/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 506.08B USD | Price to earnings Ratio 80.9 | 1Y Target Price 283.19 |
Price to earnings Ratio 80.9 | 1Y Target Price 283.19 | ||
Volume (30-day avg) 4.8M shares | Beta 0.23 | 52 Weeks Range 188.25 - 291.40 | Updated Date 10/28/2026 |
52 Weeks Range 188.25 - 291.40 | Updated Date 10/28/2026 | ||
Dividends yield (FY) 2.38% | Basic EPS (TTM) 3.54 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Immunology | Humira, Skyrizi, and Rinvoq sales. | This is the core engine of the company, though it is currently undergoing a major transition. |
| Aesthetics | Botox Cosmetic, Juvederm collection. | Provides a consumer-facing revenue stream that is less tied to traditional insurance reimbursement. |
| Neuroscience | Vraylar, Botox Therapeutic, migraine treatments. | A growing segment focused on long-term treatment needs for chronic neurological conditions. |
| Oncology | Imbruvica, Venclexta. | Highly specialized segment that targets significant unmet medical needs in cancer care. |
| Geography | Global revenue including US and International markets. | The company is largely US-centric but maintains a significant footprint in international markets. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-30 | When Before Market | Estimate 3.74 | Actual - |
Profitability
Profit Margin 9.8% | Operating Margin (TTM) 40.04% |
Management Effectiveness
Return on Assets (TTM) 10.51% | Return on Equity (TTM) 62.25% |
Valuation
Trailing PE 80.9 | Forward PE 17.61 | Enterprise Value 570.45B | Price to Sales(TTM) 7.87 |
Enterprise Value 570.45B | Price to Sales(TTM) 7.87 | ||
Enterprise Value to Revenue 8.84 | Enterprise Value to EBITDA 29.2 | Shares Outstanding 1.77B | Shares Floating 1.76B |
Shares Outstanding 1.77B | Shares Floating 1.76B | ||
Percent Insiders 0.11 | Percent Institutions 77.38 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.